Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: A hospital-based case-control study

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 5, 2011, Pages 337-341

  Zhang, Ronggui ^a   Chen, Wenjun ^a   Zhang, Weili ^a   Jiang, Qing ^a   Liu, Chuan ^a   Lin, Yanjun ^a   Hu, Zili ^a   Yu, Shengjie ^a   Xu, Guangyong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; ALLELE; ARTICLE; BLADDER CANCER; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CODON; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 79956143023     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0230     Document Type: Article

References (42)

1. Bryan RT, Hussain SA, James ND, et al. (2005a) Molecular pathways in bladder cancer: part 1. BJU Int 95:485-490. (Pubitemid 40311456)
2. Bryan RT, Hussain SA, James ND, et al. (2005b) Molecular pathways in bladder cancer: part 2. BJU Int 95:491-496. (Pubitemid 40311457)
3. Chen WC, Tsai FJ, Wu JY, et al. (2000) Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol Res 28:293-296.
4. Dai S, Mao C, Jiang L, et al. (2009) P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum Genet 125:633-638.
5. Dumont P, Leu JI, Della Pietra AC, 3rd, et al. (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365. (Pubitemid 36278852)
6. Horikawa Y, Nadaoka J, Saito M, et al. (2008) Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 20: 49-55.
7. Huang Y, Jin Y, Yan CH, et al. (2008) Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem 309:117-123.
8. Jemal A, Siegel R, Ward E, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
9. Katiyar S, Thelma BK, Murthy NS, et al. (2003) Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18- associated cervical and oral cancer in India. Mol Cell Biochem 252:117-124. (Pubitemid 37220740)
10. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239-249.
11. Kellen E, Hemelt M, Broberg K, et al. (2007) Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol 165:1221-1230. (Pubitemid 47234322)
12. Khaliq S, Hameed A, Khaliq T, et al. (2000) P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test 4:23-29. (Pubitemid 30217737)
13. Klug SJ, Ressing M, Koenig J, et al. (2009) TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 10:772-784.
14. Koushik A, Tranah GJ, Ma J, et al. (2006) p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 119:1863-1868. (Pubitemid 44356844)
15. Lee JM, Shun CT, Wu MT, et al. (2006) The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat Res 594:181-188.
16. Mabrouk I, Baccouche S, El-Abed R, et al. (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci 1010:764-770. (Pubitemid 38265078)
17. Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into the genetics of common disease. J Clin Invest 118:1590-1605. (Pubitemid 351632361)
18. Matakidou A, Eisen T, Houlston RS (2003) TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18:377-385. (Pubitemid 36850206)
19. Matlashewski GJ, Tuck S, Pim D, et al. (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961-963. (Pubitemid 17004567)
20. Mitra AP, Datar RH, Cote RJ (2006) Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 24:5552-5564. (Pubitemid 46631336)
21. Murgel de Castro Santos LE, Trindade Guilhen AC, Alves de Andrade R, et al. (2009) The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol Oncol. DOI: 10.1016/j.urolonc.2009.03.026.
22. Pashos CL, Botteman MF, Laskin BL, et al. (2002) Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 10:311-322. (Pubitemid 35231626)
23. Probst-Hensch NM, Bell DA, Watson MA, et al. (2000) N-acetyltransferase 2 phenotype but not NAT1. *10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 9:619-623. (Pubitemid 30396186)
24. Rahim NG, Harismendy O, Topol EJ, et al. (2008) Genetic determinants of phenotypic diversity in humans. Genome Biol 9:215.
25. Rohini K, Mathivanan J, Prabhu PD, et al. (2007) Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors. Mol Cell Biochem 300:101-111. (Pubitemid 46881820)
26. Rubben H, Lutzeyer W, Fischer N, et al. (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139:283-285.
27. Sorensen BS, Torring N, Bor MV, et al. (2004) The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem 260:129-135. (Pubitemid 39127580)
28. Soulitzis N, Sourvinos G, Dokianakis DN, et al. (2002) p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179:175-183. (Pubitemid 34215109)
29. Sun H, Qiao Y, Zhang X, et al. (2010) XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: a metaanalysis. Cancer Sci 101:1777-1782.
30. Tandon S, Tudur-Smith C, Riley RD, et al. (2010) A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. Cancer Epidemiol Biomarkers Prev 19:574-587.
31. Tang NP, Wu YM, Wang B, et al. (2010) Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol 36:431-438.
32. Tommiska J, Eerola H, Heinonen M, et al. (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098-5103. (Pubitemid 41003693)
33. Toruner GA, Ucar A, Tez M, et al. (2001) P53 codon 72 polymorphism in bladder cancer-no evidence of association with increased risk or invasiveness. Urol Res 29:393-395. (Pubitemid 34042185)
34. Wallerand H, Reiter RR, Ravaud A (2008) Molecular targeting in the treatmenof either advanced or metastatic bladder cancer or both according to the signalling pathways. Curr Opin Urol 18:524-532.
35. Wang M, Gu D, Zhang Z, et al. (2009) XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A 72:698-705.
36. Williams SG, Stein JP (2004) Molecular pathways in bladder cancer. Urol Res 32:373-385. (Pubitemid 40137329)
37. Zeegers MP, Kellen E, Buntinx F, et al. (2004) The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 21:392-401.
38. Zeegers MP, Tan FE, Dorant E, et al. (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89: 630-639. (Pubitemid 30640110)
39. Zeng FF, Liu SY, Wei W, et al. (2010) Genetic polymorphisms of glutathione S-transferase T1 and bladder cancer risk: a metaanalysis. Clin Exp Med 10:59-68.
40. Zhang Z, Wang M, Wu D, et al. (2010) P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysisbased on 39 case-control studies. Breast Cancer Res Treat 120:509-517.
41. Zhao Y, Wang F, Shan S, et al. (2010) Genetic polymorphism of p53, but not GSTP1, is association with susceptibility to esophageal cancer risk-a meta-analysis. Int J Med Sci 7: 300-308.
42. Zhou Y, Li N, Zhuang W, et al. (2007) P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121:1481-1486. (Pubitemid 47328706)